CASIF Stock Catalyst: CASI Pharmaceuticals Receives FDA Clearance for IND Application for CID-103

Aug 4, 2025 · 9:46am ET

The clearance allows CASI to proceed with clinical trials.

Max move

+89.0%

High of day $2.57

Sparker timei

9:46am ET

CASIF · Aug 4, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

CASI Pharmaceuticals Inc. (OTC Link: CASIF) announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its Investigational New Drug (IND) application for CID-103. This clearance enables the company to initiate clinical trials for the drug candidate.

CID-103 is a novel therapeutic candidate under development by CASI Pharmaceuticals. The IND clearance is a critical step towards evaluating the safety and efficacy of CID-103 in human trials. CASI Pharmaceuticals now has the green light to proceed with the necessary clinical studies.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time CASIF sparks.

Download Sniper App →

Catch the next CASIF-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →